Rubicon Research Limited (RUBICON) — Financial Results | 2 June 2026

StockFin.ai

Try Free

Rubicon Research reported Q4 FY26 revenue of ₹5,139 crores, up 44% YoY, with PAT rising 112% to ₹768 crores and EBITDA growing 67% to ₹1,213 crores. Full-year PAT grew 84% to ₹1,754 crores, supported by 24 products under FDA review and a 5.9x R&D productivity multiple. The company recommended a 150% dividend (₹1.5 per share) and targeted EBITDA margins of 22-23% for the upcoming quarters. Capital allocation includes INR45 crores for debt repayment and INR100 crores toward the Arinna Lifesciences acquisition, with no FY2027 acquisition specifics disclosed.

📄 View Original Announcement (PDF)

📊 Stock Analysis — RUBICON ✨ Ask AI About This

About Rubicon Research Limited (RUBICON)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹15,864.53 Cr

View full RUBICON stock details →

📡 Get AI alerts when RUBICON files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track RUBICON — Free

💡 Ask AI about this filing

"How does this financial results affect Rubicon Research Limited's outlook?" "What did Rubicon Research Limited announce on 2 June 2026?" "Is this positive or negative for RUBICON?"

Ask AI Free →

📊 More RUBICON filings

See all RUBICON filings →

🔥 Also filed on 2 June 2026

RBA Restaurant Brands Asia Limited Corporate Action RBLBANK RBL Bank Limited Insider Trading PREMEXPLN Premier Explosives Limited Financial Results PTC PTC India Limited Insider Trading RADIANTCMS Radiant Cash Management Services Limited Financial Results REFEX Refex Industries Limited Financial Results

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

📡 Get AI alerts when RUBICON files new disclosures

Track RUBICON filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track RUBICON — Free

Free account · 2 AI queries/day